|
Market Closed -
Nasdaq
04:00:00 29/08/2026 HKT
|
5-day change | 1st Jan Change | ||
| 794.19 USD | -1.67% |
|
-4.78% | +2.89% |
| 08-27 | AstraZeneca-Amgen asthma drug succeeds in late-stage oesophagus disease trial | RE |
| 08-25 | Veeva Systems Secures Biogen, Regeneron Pharmaceuticals as New Vault CRM Clients | MT |
| Market Cap | 79.3B 68.34B 64.07B 58.49B 110B 7,579B 111B 760B 297B 3,826B 298B 291B 12,686B | P/E 2026 * |
18.4x | P/E 2027 * | 15.8x |
|---|---|---|---|---|---|
| Enterprise Value | 72.44B 62.42B 58.52B 53.42B 101B 6,923B 101B 694B 271B 3,495B 272B 266B 11,588B | EV / Sales 2026 * |
4.28x | EV / Sales 2027 * | 3.73x |
| Free-Float |
71.06% | Yield 2026 * |
0.49% | Yield 2027 * | 0.56% |
Last Transcript : Regeneron Pharmaceuticals, Inc.
| 1 day | -1.67% | ||
| 1 week | -4.78% | ||
| Current month | +4.14% | ||
| 1 month | +14.20% | ||
| 3 months | +29.18% | ||
| 6 months | +1.60% | ||
| Current year | +2.89% |
| 1 week | 789.08 |  | 839.94 |
| 1 month | 724.79 | | 847 |
| Current year | 591.52 | | 847 |
| 1 year | 541 | | 847 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 19/8/26 | Fiscal year | General Counsel | 33,583 | 0.0326% | ||
| 18/8/26 | Fiscal year | Chief Financial Officer | 17,165 | 0.0167% | ||
| 10/8/26 | Fiscal year | Director | 1,200 | 0.0012% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.67% | -4.78% | +36.76% | -4.34% | 79.3B | |
| -0.90% | +2.39% | -19.06% | -35.50% | 59.21B | |
| -3.35% | -4.92% | +472.81% | +18.97% | 55.09B | |
| -6.78% | -4.19% | -3.45% | +28.35% | 49.86B | |
| -2.43% | -2.35% | +8.33% | +160.40% | 47.9B | |
| -1.35% | +0.79% | +65.25% | -18.47% | 32.28B | |
| -2.64% | -2.69% | +46.99% | +92.55% | 25.21B | |
| -0.09% | +4.98% | +11.00% | +199.86% | 23.87B | |
| -0.34% | +1.35% | +62.33% | +122.21% | 16.89B | |
| +2.73% | 0.00% | -5.13% | +831.69% | 16.17B | |
| Average | -1.68% | -1.09% | +67.58% | +139.57% | 40.58B | |
| Weighted average by Cap. | -2.21% | -1.97% | +80.30% | +73.23% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 16.92B 14.58B 13.67B 12.48B 23.51B 1,617B 23.58B 162B 63.28B 816B 63.53B 62.15B 2,707B | 18.42B 15.87B 14.88B 13.58B 25.59B 1,760B 25.67B 177B 68.88B 889B 69.15B 67.65B 2,946B |
| Net income | 4.77B 4.11B 3.86B 3.52B 6.63B 456B 6.65B 45.75B 17.85B 230B 17.92B 17.53B 764B | 5.45B 4.69B 4.4B 4.02B 7.57B 520B 7.59B 52.2B 20.37B 263B 20.44B 20B 871B |
| Net Debt | -6.87B -5.92B -5.55B -5.07B -9.54B -656B -9.57B -65.84B -25.69B -331B -25.79B -25.23B -1,099B | -10.55B -9.09B -8.53B -7.78B -14.66B -1,009B -14.71B -101B -39.47B -509B -39.62B -38.76B -1,688B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 28/08/26 | US$794.19 | -1.67% | 488,305 |
| 27/08/26 | US$807.71 | -0.87% | 766,990 |
| 26/08/26 | US$814.79 | -2.25% | 585,370 |
| 25/08/26 | US$833.56 | +0.61% | 505,424 |
| 24/08/26 | US$828.50 | -0.66% | 672,012 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
